Cancer
Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, recently developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer.
The drug was approved as a second-line treatment for HCC patients who have an alpha-fetoprotein biomarker.
Keytruda failed to show a statistical significance in overall survival and progression free survival in the Phase III trial.
Luckily, primary malignant liver tumors in children are rare. They account for only 1 to 2 percent of all childhood cancers. The most common treatment is surgery and chemotherapy. However, not all can be treated by surgery and sometimes they do not respond to chemotherapy.
PRESS RELEASES